 |
|
|
| |
Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + Dolutegravir as a 2-Drug Regimen in Treatment-Naive Adults:24-Week Results From the Phase IIb DYNAMIC Study
|
| |
| |
EACS 2023 oct 20
Samit R. Joshi,1 Mar Masia,2 Essack Mitha,3 Antonella Castagna,4 Ezequiel Cordova,5
Moti Ramgopal,6 Alison Gaudion,7 Supriya Karthika,8 James Oyee,9 Veronica Bainbridge,9
Brian Wynne,10 Max Lataillade1
1ViiV Healthcare, Branford, CT, USA; 2Infectious Diseases Unit, Hospital General Universitario de Elche, Elche, Spain;
3Newtown Clinical Research Centre, Johannesburg, South Africa; 4San Raffaele Scientific Institute and Vita-Salute San Raffaele University,
Milan, Italy; 5Fundacion IDEAA, Buenos Aires, Argentina; 6Midway Immunology and Research Center, Fort Pierce, FL, USA;
7ViiV Healthcare, Brentford, UK; 8GSK, Bangalore, India; 9GSK, Brentford, UK; 10ViiV Healthcare, Durham, NC, USA
|
| |
|
|
|
|
|
